Coeptis Therapeutics, Inc. Announces Completion of Business Combination with Bull Horn Holdings Corp.

Combined company trading as Coeptis Therapeutics Holdings, Inc. and trading on the Nasdaq Global Market under the ticker symbol “COEP”.

WEXFORD, Pa. and MIAMI, October 31, 2022 /PRNewswire/ — Coeptis Therapeutics, Inc. (“Coeptis”), a biopharmaceutical company developing innovative cell therapy platforms for cancer, today announced the completion of its business combination with Bull Horn Holdings Corp. (Nasdaq: BHSE), a special purpose company, known as an acquisition company (“Bull Horn”). In connection with the business combination, the combined company was renamed “Coeptis Therapeutics Holdings, Inc.” (the “Company”) and its public shares and warrants are expected to trade today on the Nasdaq Global Market under the ticker symbols “COEP” and “COEPW”, respectively, October 31st2022. The company will continue to focus primarily on the development of innovative cell therapy platforms for cancer patients.

In connection with the business combination, the former shareholders of Coeptis exchanged their common stock for Bull Horn common stock at a price of 2.96851721 for 1. Post the business combination, the Company has approximately 19.5 million shares of common stock issued and outstanding, with the former shareholders of Coeptis now own approximately 88% of the company and existing Bull Horn shareholders own approximately 12% of the company.

“This is a significant step for Coeptis as we strive to become a leader in the development of next-generation cell therapy technologies for cancer. This transaction closely follows our recent in-licensing of SNAP-CAR, a multi-antigen CART technology platform To be a stepping stone into what we envision for an active time with the company,” he said David Mehlick, who will lead the company as Chief Executive Officer and Chairman. “Importantly, the merger with Bull Horn has enabled our stock to be listed on the Nasdaq Global Market. The uplisting on the Nasdaq is an important aspect of our goal of increasing long-term shareholder value by potentially increasing our visibility in the investment community, increasing the liquidity of our stock and broadening our shareholder base.”

Post Completion of the Business Combination David Mehlick will serve as Chief Executive Officer and Chairman, and the remaining Coeptis leadership team will continue to serve the Company in the roles they held at Coeptis prior to the business combination. Christopher CaliseBull Horn’s chief financial officer and director, will serve on the company’s board of directors.

In light of the completion of the business combination, Bull Horn has canceled its previously scheduled extraordinary stockholders meeting November 2, 2022Vote on an amendment to the Amended and Restated Articles of Association to extend the deadline for completion of Bull Horn’s original business combination.

Advisor
Ellenoff Grossman & Schole LLP acted as legal counsel to Bull Horn and Master Seelig & Fein LLP acted as legal counsel to Coeptis. JonesTrading Institutional Services LLC provided capital markets advisory services to Bull Horn and Bridgeway Capital Partners advised Coeptis on the business combination.

About Coeptis Therapeutics Holdings, Inc.
Coeptis Therapeutics Holdings, Inc., together with its subsidiaries, including Coeptis Therapeutics, Inc. and Coeptis Pharmaceuticals, Inc., is a biopharmaceutical company developing innovative cell therapy platforms for cancer that have the potential to revolutionize traditional treatment paradigms and patient outcomes to improve. The company’s product portfolio and rights are highlighted by a universal, multi-antigen CAR-T technology licensed from University of Pittsburgh (SNAP-CAR) as well as a cell therapy technology (CD38-GEAR-NK) and an in vitro diagnostic (CD38-Diagnostic) against CD38-related cancers that the company is developing together with VyGen-Bio and leading medical researchers Karolinska Institute. The Company’s business model is designed to maximize the value of its current product portfolio and rights through in-licensing agreements, out-licensing agreements and co-development relationships, as well as entering into strategic partnerships to expand its product rights and offerings, particularly those targeted to cancer. The company was founded in 2017 and is headquartered in Wexford, PA. For more information about the company, visit https://coeptistx.com/.

Cautionary Note Regarding Forward-Looking Statements
This press release and related statements by our management contain or may contain “forward-looking statements” (as defined in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended). changed). Forward-looking statements include statements about our plans, goals, objectives, strategies, future events or performance, underlying assumptions and other statements that are not statements of historical fact. When we use words such as “may”, “will”, “intend”, “should”, “believe”, “expect”, “anticipate”, “project”, “estimate” or similar expressions that are not strictly historical matters, we make forward-looking statements. Forward-looking statements are not guarantees of future performance and involve significant risks and uncertainties that could cause actual results to differ materially, and potentially significantly, from our expectations discussed in the forward-looking statements. Factors that could cause such differences include, among others: (1) the inability to obtain or maintain a listing of the Company’s securities on the Nasdaq Global Market post the Business Combination; (2) the risk that the business combination will disrupt current plans and operations of Coeptis as a result of the consummation of the business combination; (3) the inability to realize the expected benefits of the business combination, which may be adversely affected by, among other things, competition, the company’s ability to grow and manage growth economically, and to hire and retain key employees; (4) the risks that Coeptis’ products under development will not pass clinical trials or be approved by the US Food and Drug Administration or other relevant regulatory agencies; (5) costs related to the business combination; (6) changes in applicable laws or regulations; (7) the possibility that the Company will be adversely affected by other economic, business and/or competitive factors; and (8) the impact of the global COVID-19 pandemic on any of the foregoing risks and other risks and uncertainties identified in the Company’s filings with the Securities and Exchange Commission (the “SEC”). The foregoing list of factors is not exclusive. All forward-looking statements involve significant uncertainties and risks, including, without limitation, those risks that are or may be contained in the Company’s reports and other filings with the SEC. For these reasons, among others, investors are cautioned not to place undue reliance on any forward-looking statements contained in this press release. Additional factors are discussed in the company’s filings or filings with the SEC, which are available at www.sec.gov. We undertake no obligation to publicly revise these forward-looking statements to reflect events or circumstances after the date of this release, except as required by any applicable law, rule or regulation.

CONTACTS

Coeptis Therapeutics Holdings, Inc.
investors
Tiberend Strategic Advisors, Inc.
Jon Nugent
[email protected]

media
David Shemalia
[email protected]

SOURCE Coeptis Therapeutics

source

Leave a Reply

Your email address will not be published. Required fields are marked *